Heart-racing? NASCAR picks cardiovascular partner

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
 - flag

Ladies and gentlemen, start your rrr, rrr, rrr-rivaroxaban? NASCAR, the auto racing aficionado organization, announced that Janssen Pharmaceuticals has become its official cardiovascular partner.

Janssen, maker of the anticoagulant rivaroxaban (Xarelto), is partnering with NASCAR on promotions that include prominent race car driver Brian Vickers. Vickers shares his experience with treatment after episodes of deep vein thrombosis, which temporarily sidelined his racing career. Rivaroxaban has been approved by the FDA to treat deep vein thrombosis or pulmonary embolism and to reduce the risk of recurrent deep vein thrombosis and pulmonary embolism following initial treatment.

Jannsen co-sponsored a custom “TreatMyClot.com” Toyota Camry in a recent race that coincided with National Blood Clot Awareness Month. Vickers placed seventh, according to his website, which advances him in overall points and may secure a placement in upcoming races.